We are live on ! Find out more
ATYR

aTyr Pharma
ATYR

110 hedge funds and large institutions have $336M invested in aTyr Pharma in 2025 Q2 according to their latest regulatory filings, with 52 funds opening new positions, 25 increasing their positions, 24 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

80% more capital invested

Capital invested by funds: $187M → $336M (+$150M)

79% more first-time investments, than exits

New positions opened: 52 | Existing positions closed: 29

54% more call options, than puts

Call options by funds: $5.88M | Put options by funds: $3.81M

26% more funds holding

Funds holding: 87 → 110 (+23)

5.06% more ownership

Funds ownership: 69.5% → 74.56% (+5.1%)

4% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 24

Holders
110
Holders Change
+23
Holders Change %
+26.44%
% of All Funds
1.45%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.03%
New
52
Increased
25
Reduced
24
Closed
29
Calls
$5.88M
Puts
$3.81M
Net Calls
+$2.07M
Net Calls Change
+$3.61M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$16.5M
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$4.6M
3
State Street
State Street
Massachusetts
+$3.43M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$2.55M
5
Invesco
Invesco
Georgia
+$2.35M

Top Sellers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$7.3M
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$5.82M
3
ABG
Ally Bridge Group
New York
-$1.93M
4
Goldman Sachs
Goldman Sachs
New York
-$1.36M
5
Marshall Wace
Marshall Wace
United Kingdom
-$1.29M
Name Holding Trade Value Shares
Change 		Change in
Stake
Federated Hermes
1
Federated Hermes
Pennsylvania
$74.4M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$67.7M +$1.8M +457,136 +4%
BlackRock
3
BlackRock
New York
$29.3M +$16.5M +4,188,652 +263%
Vanguard Group
4
Vanguard Group
Pennsylvania
$23.6M +$2.55M +648,313 +16%
OCA
5
Octagon Capital Advisors
New York
$19.4M +$1.05M +268,000 +8%
TM
6
Tikvah Management
North Carolina
$12.5M – – –
Geode Capital Management
7
Geode Capital Management
Massachusetts
$10.6M +$4.6M +1,170,276 +126%
UBS Group
8
UBS Group
Switzerland
$8.85M +$427K +108,531 +7%
WP
9
Woodline Partners
California
$8.53M – – –
Millennium Management
10
Millennium Management
New York
$8.11M +$4.56K +1,159 +0.1%
Alyeska Investment Group
11
Alyeska Investment Group
Illinois
$7.16M +$531K +134,852 +11%
State Street
12
State Street
Massachusetts
$6.29M +$3.43M +872,353 +237%
IHAM
13
Integral Health Asset Management
New York
$5.32M +$1.38M +350,000 +50%
Point72 Asset Management
14
Point72 Asset Management
Connecticut
$5.01M -$7.3M -1,855,422 -65%
Northern Trust
15
Northern Trust
Illinois
$3.45M +$1.94M +494,319 +265%
TCM
16
Tang Capital Management
California
$3.4M – – –
EAM
17
Erste Asset Management
Austria
$3.04M – – –
Invesco
18
Invesco
Georgia
$3.03M +$2.35M +598,008 New
Renaissance Technologies
19
Renaissance Technologies
New York
$2.63M +$151K +38,400 +8%
Marshall Wace
20
Marshall Wace
United Kingdom
$2.59M -$1.29M -327,040 -39%
GCP
21
GSA Capital Partners
United Kingdom
$2.52M +$645K +163,965 +49%
MCM
22
MAI Capital Management
Ohio
$1.87M -$1.14M -289,203 -44%
Barclays
23
Barclays
United Kingdom
$1.5M +$234K +59,495 +25%
ABG
24
Ally Bridge Group
New York
$1.46M -$1.93M -489,300 -63%
Wells Fargo
25
Wells Fargo
California
$1.41M +$430K +109,169 +65%
1
2 3 4 5

ATYR Hedge Fund Activity: Q2 2025 in Review

110 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in aTyr Pharma (ATYR) for Q2 2025, worth a combined $336M — up 80% from $187M a quarter earlier.

Buyers outnumbered sellers: 52 funds opened new ATYR positions and 29 closed out — a net gain of 23 holders — while 25 added to existing stakes and 24 trimmed.

The largest buyer was BlackRock, adding an estimated $16.5M. The largest seller was Point72 Asset Management, cutting an estimated $7.3M.

  • 110 institutional investors held aTyr Pharma (ATYR) as of Q2 2025, up from 87 in Q1 2025.
  • Funds reported $336M of aTyr Pharma stock for Q2 2025, up 80% quarter-over-quarter.
  • 52 funds opened new aTyr Pharma positions in Q2 2025 and 29 closed out, a net change of +23 holders.
  • The largest aTyr Pharma buyer in Q2 2025 was BlackRock, an estimated $16.5M added.
  • The largest aTyr Pharma seller in Q2 2025 was Point72 Asset Management, an estimated $7.3M sold.

Based on aggregated 13F filings for Q2 2025.